Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;27(2):108-114.
doi: 10.1097/MOH.0000000000000561.

Relapsed or primary refractory AML: moving past MEC and FLAG-ida

Kristin Koenig  1 , Alice Mims
Affiliations
Free PMC article
Review

Relapsed or primary refractory AML: moving past MEC and FLAG-ida

Kristin Koenig et al. Curr Opin Hematol. 2020 Mar.
Free PMC article

Abstract

Purpose of review: Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regimens.

Recent findings: Recently, advances in the treatment of relapsed/refractory AML utilizing novel chemotherapy combinations, hypomethylating, and targeted therapies have shown promising results.

Summary: Several early-phase studies with novel targeted therapy combinations have demonstrated encouraging results warranting larger, comparative studies. This has expanded the access of treatment for patients with relapsed/refractory AML who cannot receive traditional salvage chemotherapy. These newer treatments have the potential to outperform traditional chemotherapy as well.

PubMed Disclaimer

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Döhner H, Weisdorf D, Bloomfield C. Acute myeloid leukemia. N Engl J Med 2015; 373:1136–1152. - PubMed
    1. Thol F, Schlenk R, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015; 126:319–327. - PubMed
    1. Choi Y, Lee J, Lee K, et al. Treatment outcomes and prognostic factors of patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 2016; 128:4004.
    1. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424–447. - PMC - PubMed
    1. Westhus J, Noppeney R, Dührsen U, Hanoun M. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 2019; 60:1014–1022. - PubMed